Literature DB >> 15644404

Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients.

Jean-Michel Petit1, Anne Minello, Valerie Jooste, Jean Baptiste Bour, Francoise Galland, Laurence Duvillard, Bruno Verges, Niels Olivier Olsson, Philippe Gambert, Patrick Hillon.   

Abstract

OBJECTIVES: The mechanisms underlying steatosis during hepatitis C virus (HCV) infection are complex and multifactorial. Obesity is a well-recognized risk factor for the development of steatosis in chronic hepatitis C infection. The aim of our study was to investigate the role of adipocytokines in HCV-related steatosis. Therefore, we hypothesized that the endocrine function of adipose tissue could be, in part, responsible for HCV-related steatosis. Seventy-one consecutive untreated chronic hepatitis C patients were studied to assess the effects of adipocytokines, body mass index (BMI), age, and HCV genotype on steatosis. We used ELISA to determine serum adiponectin, leptin, and soluble TNF receptors I and II concentrations.
RESULTS: Steatosis was observed in 42 (59.1%) patients. BMI was significantly associated with leptin (r = 0.64; P = 0.0001) and was border significantly associated with adiponectin concentrations (r = -0.22; P = 0.06). In univariate analyses, age, HCV genotype 3, BMI, increased leptin level, increased insulin level, and decreased adiponectin concentration were associated with steatosis. In multivariate analysis, steatosis was significantly associated with low adiponectin concentration, age, HCV genotype 3, and aspartate aminotransferase (ASAT) level, whereas steatosis was not associated with leptin, insulin, and BMI.
CONCLUSION: In chronic HCV patients, hypoadiponectinemia is significantly associated with the development of liver steatosis. The fact that the plasma levels of adiponectin inversely correlate with steatosis in HCV-infected subjects suggests that hypoadiponectinemia may contribute to hepatic steatosis progression and liver injury in this population. One practical implication is that therapy to increase circulating adiponectin concentration, such as overweight reduction or thiazolidinediones, provides the potential to improve steatosis in chronic hepatitis C infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644404     DOI: 10.1210/jc.2004-1266

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Study of adiponectin in chronic liver disease and cholestasis.

Authors:  Tary A Salman; Naglaa Allam; Gasser I Azab; Ahmed A Shaarawy; Mona M Hassouna; Omkolsoum M El-Haddad
Journal:  Hepatol Int       Date:  2010-10-09       Impact factor: 6.047

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  [Current problems of hepatitis].

Authors:  H P Dienes; U Drebber
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 4.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

Review 5.  Hepatitis C in hemodialysis patients.

Authors:  Smaragdi Marinaki; John N Boletis; Stratigoula Sakellariou; Ioanna K Delladetsima
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

Review 7.  Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Authors:  Valentina Peta; Carlo Torti; Natasa Milic; Alfredo Focà; Ludovico Abenavoli
Journal:  World J Hepatol       Date:  2015-01-27

Review 8.  Insulin resistance and steatosis in hepatitis C virus infection.

Authors:  A Zekry; J G McHutchison; A M Diehl
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

9.  Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis.

Authors:  Emilio González-Reimers; Javier López-Prieto; Geraldine Quintero-Platt; Ricardo Pelazas-González; M Remedios Alemán-Valls; Onán Pérez-Hernández; M José de-la-Vega-Prieto; M Angeles Gómez-Rodríguez; Candelaria Martín-González; Francisco Santolaria-Fernández
Journal:  World J Hepatol       Date:  2016-01-08

Review 10.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.